Printer Friendly

DIANON SYSTEMS, INC. ANNOUNCES THE LAUNCH OF A NATIONAL PROGRAM TO SCREEN FOR PROSTATE CANCER

 STRATFORD, Conn., Feb. 10 /PRNewswire/ -- DIANON Systems, Inc. (NASDAQ: DIAN) announced today the national launch of its Prostate Cancer Early Detection Program to urologists in the United States. Working in conjunction with TAP Pharmaceutical Inc., DIANON Systems will be contacting urologists to set up local screening programs which will utilize DIANON Systems' unique Prostate Cancer Early Detection Program.
 Combining the results from the urologist's physical examination of the prostate, DIANON Systems' blood test for prostate-specific antigen and the patient's age -- DIANON Systems can provide urologists with a prostate cancer risk assessment.
 Jack Davis, president and co-CEO announced today that the two companies' combined sales forces of approximately 500 sales representatives expect to screen at least 200,000 men over the next twelve months.
 James Amberson, M.D., vice president of Pathology Services estimated that 165,000 men would be diagnosed with prostate cancer this year in the United States and stated that, among all types of cancer, prostate cancer is exceeded only by lung cancer as a cause of death in men over 50.
 DIANON Systems provides innovative laboratory services and information products to physicians in oncology and gynecology.
 -0- 2/10/93
 /CONTACT: Richard A. Sandberg, chairman and co-chief executive officer, 203-381-4022, Jack Davis, president and co-chief executive officer, 203-381-4033, both of
 (DIAN)


CO: DIANON Systems, Inc.; TAP Pharmaceutical Inc. ST: Connecticut IN: MTC SU: PDT

TS -- NY079 -- 5309 02/10/93 16:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:236
Previous Article:FIDELITY MANAGEMENT AND RESEARCH COMPANY PURCHASES AGNICO-EAGLE MINES COMMON STOCK
Next Article:MOODY'S ASSIGNS 'A' RATING TO SALT LAKE CITY'S JUNIOR LIEN AIRPORT REVENUE BONDS
Topics:


Related Articles
DIANON SYSTEMS REPORTS AUDITED RESULTS FOR THE YEAR ENDED DEC. 31, 1991
DIANON SYSTEMS, INC. ANNOUNCES THE PURCHASE OF COLLABORATIVE DIAGNOSTICS
DIANON SYSTEMS, INC. REPORTS SECOND QUARTER SALES AND EARNINGS
DIANON SYSTEMS, INC. ACQUIRES EXCLUSIVE RIGHTS TO A UNIQUE CANCER TEST FROM M.D. ANDERSON CANCER CENTER
DIANON SYSTEMS, INC. SIGNS AGREEMENT WITH JAPANESE LABORATORY FOR GENETIC TESTING
DIANON SYSTEMS, INC. REPORTS SECOND QUARTER SALES AND EARNINGS
DIANON SYSTEMS, INC. REPORTS FOURTH QUARTER SALES AND EARNINGS
DIANON Systems Receives Second Patent For Next-Generation Prostate Specific Antigen
DIANON Systems Announces Results from Largest Studies to Date of New Prostate Cancer Test - Development of A Statistical Model to Reduce Number of...
DIANON Systems, Inc. Launches Presurgical Staging Tool for Prostate Cancer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters